

Adbry® (tralokinumab-ldrm)

We're Collecting Info on Adbry® When Taken in Pregnancy

MotherToBaby is currently enrolling participants into an observational study examining the use of Adbry® (tralokinumab-ldrm) when taken during pregnancy. **Our research is by observation only—we will not ask you to take or change any medications.** If you join our Adbry® study, our team will simply collect some information about your pregnancy and your baby's development for a period of time after birth.

"Help us improve the ability for pregnant people and their healthcare providers to make more informed treatment decisions by joining our Adbry® & Pregnancy Study."

— Christina Chambers, PhD, MPH, Lead Investigator, MotherToBaby Pregnancy Studies

Our study includes:

- 1-3 phone interviews during your pregnancy and at least 1 interview after you have your baby.
- Your permission to obtain a copy of your and your baby's medical records from your healthcare providers.
- An opportunity to receive a specialized, non-invasive exam of your baby with a study doctor.
- A neurodevelopmental assessment that can also provide insight into the child's development at approximately 4 months and 12 months of age

If you have moderate-to-severe eczema (atopic dermatitis) and have taken Adbry® (tralokinumab-ldrm) at any point in your current pregnancy or 3 months prior to pregnancy, you may qualify for this important study. Will you take the next step and help us learn more about the use of Adbry® (tralokinumab-ldrm) during pregnancy?

[JOIN A STUDY](#)[REFER A PATIENT](#)

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, December 8, 2022.

Adbry® (tralokinumab-ldrm)

Help Us Understand the Possible Effects of Benlysta® in Pregnancy

Many people need to take medication during pregnancy to appropriately manage a chronic health condition. In some cases, avoiding or stopping medication use during pregnancy may be more harmful than taking medication. Yet fewer than 10% of medications have enough information to determine their safety for use in pregnancy — this is where you come in!

MotherToBaby is currently enrolling pregnant women in a study examining the use of Benlysta® (belimumab) to treat systemic lupus erythematosus (or SLE, a type of lupus) or active lupus nephritis (lupus-related kidney inflammation) during pregnancy.

Are you currently pregnant? Did you take Benlysta® at any point in your current pregnancy? If you answered “yes” to both of these questions, then you have the opportunity to help us learn more about Benlysta®.

"There is a huge need to generate more data for all of the drugs that people who are pregnant need to take."

— Christina Chambers, PhD, MPH, Lead Investigator, MotherToBaby Pregnancy Studies

Will you take the next step and become our partner? Make an impact on the health of future families today by joining our Benlysta® & Pregnancy Study!

JOIN A STUDY

REFER A PATIENT

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, December 8, 2022.

Adbry® (tralokinumab-ldrm)

When you think medication or vaccine safety, you think clinical drug trials. Right?! Clinical drug trials are research studies designed to gather information to determine whether a new medication or vaccine is safe and effective in people.

However, what most people don't know is that pregnant women are excluded from these studies when a new drug is being developed. Essentially, this means that once a medication is approved by the US Food & Drug Administration

(FDA), it's prescribed to patients (including those who are or could become pregnant) with little to no information on the safety of the drug if used during pregnancy. Currently, less than 10% of medications approved by the FDA have enough information to determine their risk when used in pregnancy! To address this gap, the FDA may require observational studies, called pregnancy exposure registries, to be conducted on newly approved medications or vaccines to determine safety in pregnancy.

What are pregnancy exposure registries?

Pregnancy exposure registries are observational studies that collect health information on exposure to medical products such as drugs and vaccines during pregnancy. "Observational" means that study participants are **never** asked to take a new medication or to change any existing medications. After enrolling in the study they are simply followed by researchers through the remainder of their pregnancy, often by completing interviews or surveys or by allowing the researchers to access their medical records.

Why are pregnancy exposure registries important?

Pregnant women represent an important segment of the population, with over 6 million pregnancies occurring per year the U.S. alone. Additionally, studies have shown that 9 out of 10 women take medication during pregnancy – these women deserve to know if the medications they are taking will have any effect on their pregnancy, and pregnancy exposure registries are how we gather this information.

**9 out of 10
women take
medication during
pregnancy.**



This information is used by pharmaceutical companies when listing safety information on drug labels. It is also helpful for healthcare providers to determine treatment plans for their pregnant patients. In many cases, pregnancy exposure registries have provided reassurance – and in some cases have raised red flags – on whether a medication is safe to take during pregnancy.

Why not just stop taking medications before you become pregnant?

It's a common misconception that quitting a medication during pregnancy will be safer for the mom and her baby. In fact, for many chronic health conditions (such as asthma or seizure disorders), it's safer for both mom and baby if the condition is well-managed. Some pregnant women may also experience acute conditions (like an infection) or develop complications during pregnancy that require medication. Physicians and pregnant women have the difficult task of balancing the risks and effects of an unmanaged condition during pregnancy versus the potential risks and benefits of starting or continuing to take a medication during pregnancy. Having enough information about the safety of the medication when used in pregnancy would make this task a whole lot easier.

**Balancing the potential
benefits and risks
of taking a medication
during pregnancy.**



And let's not forget: nearly half of all pregnancies in the U.S. may be unintended, which means that women may be exposing their pregnancy to a medication without realizing it because they weren't planning the pregnancy and won't know they are pregnant until they miss their first menstrual period.

How are registries organized/structured?

It's worth repeating: Pregnancy registries are **strictly observational**. Researchers will follow participants throughout their pregnancy and sometimes after the child has been born regardless of the woman's healthcare routine.

Researchers collect data about the pregnancy from the woman and/or (with the woman's permission) from her medical records. The type of data collected, communications and length of participation vary from one registry to another, so it's important you find out all the details about the study before you join.

Here are some basic questions you can ask or think about to make an informed decision about participating:

- What information about my pregnancy will be gathered and how will it be collected?
- How long do I participate?
- How will my information be protected?
- Will they let me know the outcome of the study after it's completed?
- How will my participation help me and other pregnant women?

Here are some basic questions you can ask or think about to make an informed decision about participating:

What information about my pregnancy will be gathered and how will it be collected?



How long do I participate?



How will my information be protected?



Will they let me know the outcome of the study after it's completed?



How will my participation help me and other pregnant women?



Who participates?

Pregnancy registries are generally designed to compare pregnant women who have been exposed to the medication/vaccine of interest to those who have not been exposed. Depending on the registry, participants can include women who:

- Have taken a specific medication or vaccine during a current or recent pregnancy.
- Are pregnant and have not taken the medication being studied, but have the same health condition being treated by the medication being studied.
- Are pregnant, have not taken the medication being studied, and do not have the same health condition being studied.

Where can I find a registry to join?

There are a variety of organizations that run pregnancy registries. A great place to start is by asking your healthcare provider. You can also look on the [US FDA Pregnancy Registry](#) site.

What makes MotherToBaby pregnancy registries different?

Here at MotherToBaby, we run several pregnancy exposure registries, called MotherToBaby Pregnancy Studies. Our studies are unique in a few different ways:

- Participants have access to our trained experts to answer questions on any exposures during pregnancy and breastfeeding – all at no cost to you.
- Some of our studies offer a free in-home examination of your infant and a consultation with an expert pediatric specialist who can answer any questions you might have about your child's growth and development.
- When you enroll in a study that includes free developmental follow-up for your child, you'll receive reports after each screening, which will provide you with information about how your child is developing relative to other children his/her age.

Interested in learning more about what it's like to participate in our studies? Meet Mariah, a study participant and maternal health advocate mom of 4. She shares her experience [here](#).

If you or someone you know is interested in joining one of our pregnancy studies, we'd be happy to talk you through the process and answer any questions you may have.

- **Call 877.311.8972 or email MotherToBaby@health.ucsd.edu**

You can also browse through our ongoing studies [here](#).

[avatar size="300"]

[mtb_post_author_meta field="display_name"], [mtb_post_author_meta field="description"]

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, December 8, 2022.

Adbry® (tralokinumab-ldrm)

Help Us Better Understand the Possible Effects of Ilumya® in Pregnancy

Many people need to take medication during pregnancy to appropriately manage a chronic health condition. In some cases, avoiding or stopping medication use during pregnancy may be more harmful than taking medication. Yet fewer than 10% of medications have enough information to determine their safety for use in pregnancy — this is where you come in!

MotherToBaby is currently enrolling people who are pregnant in a study examining the use of Ilumya® (tildrakizumab-asmn) to treat psoriasis during pregnancy.

“There is a huge need to generate more info for all of the drugs that people who are pregnant need to take.”

--- Christina Chambers, PhD, MPH, Lead Investigator, MotherToBaby Pregnancy Studies

Are you currently pregnant? Did you take Ilumya® at any point in your current pregnancy? If you answered “yes” to both of these questions, then you have the opportunity to help us learn more about Ilumya® use in pregnancy.

Will you take the step and become our partner? Make an impact on the health of future families today by joining our Ilumya® & Pregnancy Study!

JOIN A STUDY

REFER A PATIENT

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, December 8, 2022.

Adbry® (tralokinumab-ldrm)

Help Us Better Understand the Possible Effects of Tremfya® in Pregnancy

Many people need to take medication during pregnancy to appropriately manage a chronic health condition. In some cases, avoiding or stopping medication use during pregnancy may be more harmful than taking medication. Yet fewer than 10% of medications have enough information to determine their safety for use in pregnancy — this is where you come in!

MotherToBaby is currently enrolling people in a study examining the use of Tremfya® (guselkumab) to treat psoriasis, psoriatic arthritis, Crohn's disease, or ulcerative colitis during pregnancy.

"There is a huge need to generate more info for all of the drugs that people who are pregnant need to take."

--- Christina Chambers, PhD, MPH, Lead Investigator, MotherToBaby Pregnancy Studies

Are you currently pregnant? Did you take Tremfya® at any point in your current pregnancy? If you answered "yes" to both of these questions, then you have the opportunity to help us learn more about Tremfya® use in pregnancy.

Will you take the step and become our partner? Make an impact on the health of future families today by joining our Tremfya® & Pregnancy Study!

JOIN A STUDY

REFER A PATIENT

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, December 8, 2022.